Inter J Plant Based Pharma
Discussion As diets high in protein are theoretically advantageous for patients with T2D and obesity due to their satiating properties compared with carbohydrate- and lipid-rich meals [25,26,27], specific amino acids selected for their appetite-reducing and GLP-1 stimulating effect may represent an approach for nutritionally based modulation of GLP-1 secretion
At higher, maximally efficacious semaglutide doses, food intake suppression appears to approach a physiological lower limit of approximately 1 g/day, beyond which additional anorectic effect is minimal [27]
The GLP-1R is a G-protein coupled receptor that has wide tissue expression, including in the brain, the wall of the portal vein near the hilus of the liver, and arteries and arterioles from various organs (kidney, heart, pancreas, and intestine) [18]
Wegovy (semaglutide 2.4 mg) is for weight loss and CV risk reduction the anti-obesity benefit is typically excluded on ACA individual plans
